Back to all news
Deep Learning Model Enables 3D Handheld Photoacoustic-Ultrasound Imaging Without Sensors
Pusan National University develops MoGLo-Net, an AI model that reconstructs 3D images from handheld 2D photoacoustic and ultrasound scans without external sensors.
Key Details
- 1MoGLo-Net uses deep learning to track handheld ultrasound transducer motion from tissue speckle data, eliminating need for external tracking hardware.
- 2Combines ResNet-based encoder and LSTM-based motion estimator for accurate motion tracking and 3D reconstruction.
- 3Validated using both proprietary and public datasets, outperforming state-of-the-art methods on all metrics.
- 4Successfully achieved 3D blood vessel reconstructions from combined ultrasound and photoacoustic data.
- 5Published June 13, 2025, in IEEE Transactions on Medical Imaging (DOI: 10.1109/TMI.2025.3579454).
- 6Innovation aims to make advanced 3D imaging safer, more accurate, and accessible without costly hardware.
Why It Matters
MoGLo-Net's ability to reconstruct 3D volumes from standard handheld imaging without external sensors could democratize high-end ultrasound and photoacoustic imaging, especially important in resource-limited settings. This advance may enable more effective diagnosis and real-time imaging guidance, expanding access to advanced imaging technologies while reducing costs and complexity of equipment.
Source
EurekAlert
Related News
•EurekAlert
New VIS-Fb Nanobody Probes Transform High-Precision Cellular Imaging
Salk and Einstein researchers have developed visible-spectrum antigen-stabilizable fluorescent nanobodies (VIS-Fbs) for sharper, multi-color live-cell imaging with minimal background noise.
•EurekAlert
NIH-Backed AI Model Predicts Cancer Survival Using Single-Cell Data
Researchers have developed scSurvival, a machine learning tool that uses single-cell tumor data to accurately predict cancer patient survival and identify high-risk cell populations.
•EurekAlert
AI Pathology Model Outperforms PD-L1 in Predicting NSCLC Immunotherapy Response
MD Anderson's Path-IO machine learning platform accurately predicts immunotherapy responses in metastatic non-small cell lung cancer, surpassing current biomarker standards.